AI assistant
TENAX THERAPEUTICS, INC. — Director's Dealing 2021
Jun 15, 2021
34835_dirs_2021-06-15_416bc5af-c448-470c-804b-03c67167367a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TENAX THERAPEUTICS, INC. (TENX)
CIK: 0000034956
Period of Report: 2021-06-11
Reporting Person: Davidson Michael H. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-11 | Common Stock | A | 512000 | — | Acquired | 606645 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-10 | Stock Option (right to buy) | $2.00 | A | 6250 | Acquired | 2031-06-10 | Common Stock (6250) | Direct |
| 2021-06-11 | Series B Preferred Stock | $ | M | 512 | Disposed | 2021-06-11 | Common Stock (512000) | Direct |
Footnotes
F1: On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021.
F2: As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction.